Xiamen Amoytop Biotech Stock Total Asset
| 688278 Stock | 76.15 2.00 2.56% |
Xiamen Amoytop Biotech fundamentals help investors to digest information that contributes to Xiamen Amoytop's financial success or failures. It also enables traders to predict the movement of Xiamen Stock. The fundamental analysis module provides a way to measure Xiamen Amoytop's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xiamen Amoytop stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 2.7 B | 2.8 B |
Xiamen | Total Asset |
Xiamen Amoytop Biotech Company Total Asset Analysis
Xiamen Amoytop's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Xiamen Amoytop Total Asset | 2.36 B |
Most of Xiamen Amoytop's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xiamen Amoytop Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Xiamen Total Assets
Total Assets |
|
Based on the latest financial disclosure, Xiamen Amoytop Biotech has a Total Asset of 2.36 B. This is 68.67% lower than that of the Biotechnology sector and 19.24% higher than that of the Health Care industry. The total asset for all China stocks is 92.0% higher than that of the company.
Xiamen Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xiamen Amoytop's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xiamen Amoytop could also be used in its relative valuation, which is a method of valuing Xiamen Amoytop by comparing valuation metrics of similar companies.Xiamen Amoytop is currently under evaluation in total asset category among its peers.
Xiamen Fundamentals
| Return On Equity | 0.4 | ||||
| Return On Asset | 0.22 | ||||
| Profit Margin | 0.29 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 30.4 B | ||||
| Shares Outstanding | 406.8 M | ||||
| Shares Owned By Insiders | 67.08 % | ||||
| Shares Owned By Institutions | 16.59 % | ||||
| Price To Book | 13.68 X | ||||
| Price To Sales | 11.00 X | ||||
| Revenue | 2.1 B | ||||
| Gross Profit | 2.82 B | ||||
| EBITDA | 1.02 B | ||||
| Net Income | 555.45 M | ||||
| Total Debt | 4.16 M | ||||
| Book Value Per Share | 5.57 X | ||||
| Cash Flow From Operations | 512.1 M | ||||
| Earnings Per Share | 1.82 X | ||||
| Target Price | 72.51 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 30.98 B | ||||
| Total Asset | 2.36 B | ||||
| Retained Earnings | 955.01 M | ||||
| Working Capital | 936.53 M | ||||
| Net Asset | 2.36 B | ||||
| Last Dividend Paid | 0.41 |
About Xiamen Amoytop Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xiamen Amoytop Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xiamen Amoytop using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xiamen Amoytop Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Xiamen Stock
Xiamen Amoytop financial ratios help investors to determine whether Xiamen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xiamen with respect to the benefits of owning Xiamen Amoytop security.